Author:
McNamara Keely M,Guestini Fouzia,Sauer Torill,Touma Joel,Bukholm Ida Rashida,Lindstrøm Jonas C,Sasano Hironobu,Geisler Jürgen
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. American Cancer Society. Cancer Facts & Figures. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html (2016).
2. Geisler, J. & Lonning, P. E. Aromatase inhibition: translation into a successful therapeutic approach. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 11, 2809–2821 (2005).
3. Baselga, J. et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26, 78–83 (1999).
4. Lonning, P. E. et al. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J. Steroid Biochem. Mol. Biol. 117, 31–41 (2009).
5. McNamara, K. M., Guestini, F., Sakurai, M., Kikuchi, K. & Sasano, H. How far have we come in terms of oestrogens in breast cancer? Endocr. J. 63, 413–424 (2016).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献